诺诚健华在2025年美国ASCO年会发布一系列创新管线最新数据

Core Viewpoint - The company announced the presentation of innovative pipeline data at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, highlighting advancements in its drug candidates [1] Group 1: Pipeline Innovations - The company will present data on the anti-CCR8 antibody ICP-B05 (CM369) [1] - The company will showcase findings related to the BCL2 inhibitor mesutoclax (ICP-248) [1] - The company will also introduce updates on the pan-TRK inhibitor zurletrectinib (ICP-723) [1]